Elena Geretti,Victor Moyo,Joseph G. Reynolds,Thomas Wickham
申请号：
US14819317
公开号：
US20160045596A1
申请日:
2015.08.05
申请国别(地区):
US
年份:
2016
代理人:
摘要：
Methods for treating cancer patients (e.g., cancer patients resistant or intolerant to pertuzumab and ado-trastuzumab emtansine) having HER2-positive tumors are disclosed. The methods comprise administering to a patient a therapeutically effective amount of a combination of a doxorubicin-loaded immunoliposome with a targeting moiety that is an anti-HER2 antibody that is not an inhibitor of HER2 signaling and an anti-cancer therapeutic comprising a doxorubicin-free anti-cancer therapeutic comprising a different anti-HER2 antibody.
